Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Trial Profile

Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Autoimmune disorders; Dermatomyositis; Skin disorders
  • Focus Expanded access; Therapeutic Use
  • Acronyms JAGAT
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 09 Nov 2021 Results (n=10) assessing disease flares in CANDLE/PRAAS with dose reductions of baricitinib, presented at the ACR Convergence 2021
    • 09 Nov 2021 Results (n=4) assessing Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis presented at the ACR Convergence 2021
    • 14 Nov 2017 Results of pooled data from two trial (NCT02974595 and NCT01724580) assessing pharmacokinetics, pharmacodynamics and oral dosing regimen of baricitinib in patients with rare interferonopathies, were published in the Clinical Pharmacology and Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top